Pharmacogenomics in the evaluation of efficacy and adverse events during clinical development of vaccines

Methods in Molecular Biology

Volumn 448, Issue , 2008, Pages 469-479

  Nilsson, Lennart J ^a   Regnström, Karin J ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Adverse reactions; Clinical study; Efficacy; Microarray; PBMCs; Pharmacogenomics; Vaccine

Indexed keywords

EID: 84934435015     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-205-2_17     Document Type: Article

References (17)

1. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research Washington D.C. Preliminary guidelines for the manufacture and evaluation of DNA vaccines. (1996) Docket 96N-0400.
2. Pilaro, A.M., and Serabian, M.A. (1999) Preclinical development strategies for novel gene therapeutic products. Toxicol. Pathol. 27, 4-7.
3. Fauci, A.S. (2001) Infectious diseases: considerations for the 21st century. Clin. Infect. Dis. 32, 675-685.
4. Pauwels, R., van der Straeten, M., Platteau, B., and Bazin, H. (1983) The non-specific enhancement of allergy. In vivo effects of Bordetella pertussis vaccine on IgE synthesis. Allergy. 38, 239-246.
5. Dhiman, N., Bornilla, R., O'Kane, D.J., and Poland, G.A. (2001) Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine. 20, 22-30.
6. Regnström, K., Ragnarsson, E.G.E., Rydell, N., Sjöholm, I., and Artursson, P. (2002) Tetanus antigen modulates the gene expression profile of aluminum phosphate adjuvant in spleen lymphocytes in vivo. Pharmacogenom. J. 2, 57-64.
7. Regnström, K., Ragnarsson, E.G.E., and Artursson, P. (2003) Gene expression after vaccination of mice with formulations of diphtheria- or tetanus toxoid and different adjuvants: arrays identify shared immune response genes and vaccine-specific genes in spleen lymphocytes. Vaccine. 21, 2307-2317.
8. Regnström, K., Ragnarsson, E.G.E., Köping-Höggård, M., Torstensson, L., Nyblom, N., and Artursson, P. (2003) PEI-a potent, but not harmless, mucosal immunostimulator of mixed T-helper cell response and FasL mediated cell death in mice. Gene Ther. 10, 1575-1583.
9. Regnström, K., Ragnarsson, E.G.E., Fryknäs, M., Köping-Höggård, M., and Artursson, P. (2006) Gene expression profiles in mouse lung tissue after administration of two cationic polymers used for non-viral gene delivery. Pharm. Res. 23, 475-482.
10. Regnström, K., and Burgess, D. (2006) Pharmacogenomics and its potential impact on drug and formulation development. Crit. Rev. Ther. Drug Carrier Syst. 22, 465-492.
11. Slonim, D.K. (2001) Transcriptional profiling in cancer: the clinical pathway to pharmacogenomics. Pharmacogenomics. 2, 123-136.
12. Lesko, L.J., and Woodcock, J. (2004) Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat. Rev. Drug Discov. 3, 763-769.
13. Food and Drug Administration (FDA). Guidance for industry, pharmacogenomics data submissions. Available at: http://www.fda.gov/cber/gdlns/ pharmdtasub.htm. Accessed March 31, 2005.
14. Olin, P., Rasmussen, F., Gustafsson, L., Hallander, H.O., and Heijbel, H. (1997) Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet. 350, 1569-1577.
15. Gustafsson, L., Hallander, H.O., Olin, P., Reizenstein, E., Storsaeter, J. (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334, 349-355.
16. Odent, M.R., Culpin, E.E., and Kimel, T. (1994) Pertussis vaccination and asthma: is there a link? JAMA. 272, 929-931.
17. Kemp, T., Pearce, N., Fitzharris, P., et al. (1997) Is infant immunization a risk factor for childhood asthma or allergy? Epidemiology. 8, 678-680.